CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Predictors of Coronary Stent ThrombosisThe Dutch Stent Thrombosis Registry
Jochem W. van Werkum, MD*, ,
Antonius A. Heestermans, MD ,
A. Carla Zomer, MD*,
Johannes C. Kelder, MD*,
Maarten-Jan Suttorp, MD, PhD*,
Benno J. Rensing, MD, PhD*,
Jacques J. Koolen, MD, PhD ,
B.R. Guus Brueren, MD, PhD,
Jan-Henk E. Dambrink, MD, PhD,
Raymond W. Hautvast, MD, PhD||,
Freek W. Verheugt, MD, PhD and
Jurriën M. ten Berg, MD, PhD*,*
* Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands
Department of Cardiology, UMC St. Radboud Nijmegen, Nijmegen, the Netherlands
Department of Cardiology, Isala klinieken, Zwolle, the Netherlands
Department of Cardiology, Catharina ziekenhuis Eindhoven, Eindhoven, the Netherlands
|| Department of Cardiology, Alkmaar Medisch Centrum, Alkmaar, the Netherlands
Manuscript received August 21, 2008;
revised manuscript received December 15, 2008,
accepted December 18, 2008.
* Reprint requests and correspondence: Dr. Jurriën M. ten Berg, Department of Cardiology, St. Antonius Hospital, P.O. Box 2500, 3435 CM Nieuwegein, the Netherlands (Email: berg03{at}antonius.net).
 |
Abstract
|
|---|
Objectives: This study sought to comprehensively identify predictors of stent thrombosis (ST).
Background: Given the devastating consequences of ST, efforts should be directed toward risk stratification to identify patients at highest risk for ST.
Methods: Consecutive patients with angiographic ST were enrolled. Patients who did not suffer from a ST were randomly selected in a 2:1 ratio and were matched for: 1) percutaneous coronary intervention (PCI) indication; 2) same date of index PCI; and 3) same interventional center.
Results: Of 21,009 patients treated with either a bare-metal or drug-eluting stent, 437 patients (2.1%) presented with a definite ST. A total of 140 STs were acute, 180 were subacute, 58 were late, and 59 were very late. Undersizing of the coronary stent, Thrombolysis In Myocardial Infarction flow grade <3, present malignancy, presence of intermediate coronary artery disease proximal and distal to the culprit lesion, dissection, lack of aspirin, bifurcation lesions, ejection fraction <30%, and younger age were associated with ST. The lack of clopidogrel therapy at the time of ST in the first 30 days after the index PCI (hazard ratio [HR]: 36.5, 95% confidence interval [CI]: 8.0 to 167.8), between 30 days and 6 months after the index PCI (HR: 4.6, 95% CI: 1.4 to 15.3), and beyond 6 months (HR: 5.9, 95% CI: 1.7 to 19.8) after the index PCI was strongly associated with ST.
Conclusions: Important correlates of ST were identified. Discontinuation of clopidogrel, undersizing of the coronary stent, present malignancy, and intermediate ( 50% to <70% stenosis) coronary artery disease proximal to the culprit lesion were the strongest predictors of ST.
Key Words: bare-metal stent • clopidogrel • drug-eluting stent • predictors • stent thrombosis
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | BMS = bare-metal stent(s) | | CAD = coronary artery disease | | CI = confidence interval | | DES = drug-eluting stent(s) | | HR = hazard ratio | | IVUS = intravascular ultrasound | | LVEF = left ventricular ejection fraction | | NSTEMI = non–ST-segment elevated myocardial infarction | | PCI = percutaneous coronary intervention | | ST = stent thrombosis | | STEMI = ST-segment elevated myocardial infarction | | TIMI = Thrombolysis In Myocardial Infarction |
|
Despite improved stent implantation technologies and more effective antiplatelet regimens, stent thrombosis (ST) continues to occur with an estimated incidence varying between 1% and 5% (1–6). This wide variability in the estimated incidence strongly indicates the multifactorial nature of the phenomenon of ST.
Several observational studies have identified a number of clinical, angiographic, and procedural determinants of ST. These studies are hampered, however, by small sample size, retrospective character of study design, and variation in the definition of ST (1–5,7). Consequently, less-frequent but clinically meaningful risk factors could not be explored, and the multivariate analysis model was overfitted in the majority of studies. Furthermore, these studies did not focus on possible differences in underlying pathophysiological mechanisms between: 1) different indications of stent implantation (stable angina vs. acute coronary syndromes [ACS]); and 2) early versus late ST.
Because recognition of risk factors attributable to ST might help to improve prognosis by the development of a risk-stratification model, we sought to identify predictors of early and late ST and to determine predictors of ST in different populations (stable angina and ACS, non–ST-segment elevated myocardial infarction [NSTEMI] and ST-segment elevated myocardial infarction [STEMI]) in a "real world" of mixed bare-metal stent (BMS) and drug-eluting stent (DES) use. Given the detailed character of our study, we were also able to study the impact of the clopidogrel discontinuation on the occurrence of ST at the different time points after the index procedure.
|
Methods
|
|---|
Study design and population.
The Dutch stent thrombosis registry is a large-scale, multi-centre study conducted in 3 high-volume centers in the Netherlands (>2,500 interventions/center/year). All consecutive patients with an angiographically confirmed ST presenting to the participating centers from January 2004 to February 2007 were enrolled. Stent thrombosis was defined according to the Academic Research Consortium criteria for "definite" ST (8). Clinical criteria consisted of a new episode of chest pain and/or ischemic electrocardiographic changes and/or increase of cardiac biomarkers release. Angiographic criteria consisted of partial or complete occlusion within the previously implanted stent with evidence of fresh thrombus. On the basis of the elapsed time since stent implantation, ST was classified as acute (intraprocedural or within 24 h of the procedure), subacute (from 24 h to 30 days), late (>30 days to 1 year), or very late (>1 year). Acute and subacute ST were also defined as early ST. Likewise, late and very late ST were defined as late ST.
Matched Control Group
Patients who underwent percutaneous coronary intervention (PCI) with stent implantation but with no evidence of ST during follow-up were recruited and served as control subjects in a 2:1 ratio. Control subjects were individually matched to case subjects by the following criteria: 1) similar indication (either stable angina or ACS [NSTEMI, STEMI]) for the index-PCI procedure; 2) same date of the index PCI procedure (±1 day in a minority of STEMI patients); and 3) same performing institution.
Procedural details and adjunctive medical therapy.
The PCI was performed by standard techniques via the femoral approach in most cases. During PCI, patients were anticoagulated with 70 IU/kg of unfractionated heparin. All patients were treated with aspirin (80 to 100 mg) before PCI and were loaded with clopidogrel (300 to 600 mg) if they were not taking maintenance therapy. Aspirin was continued indefinitely. The recommended duration of clopidogrel therapy after the index PCI varied from 4 weeks after BMS implantation during elective angioplasty to 3 to 12 months with DES. For patients presenting with ACS, 12 months clopidogrel therapy was recommended, regardless of the stent type used. The use of adjunctive devices (e.g., thrombus aspiration catheter) or glycoprotein IIb/IIIa therapy was at the operators' discretion.
Data collection.
Detailed data on patient, angiographic, and procedural characteristics for both the cases and control subjects were collected. Comprehensive information about the use of antithrombotic therapy (i.e., aspirin, clopidogrel, Coumadin) at the time of the index PCI was also collected. The duration of clopidogrel use as well as aspirin compliance after patient discharge was assessed with telephonic patient interview as well as data from pharmacy records (the date of clopidogrel dispensed and the number of days supplied for each dispense). In case of disagreement, the pharmacy data were used for the analysis.
Angiographic analysis.
Angiograms of both the cases and the control subjects were reviewed by 2 experienced interventional cardiologists who were blinded to the objectives of this study and outcome data. Calcification was identified as readily apparent radio-opacities within the vascular wall. Angiographic thrombus was defined as a filling defect seen in multiple projections surrounded by contrast in the absence of calcification. Angiographically visible, uncovered dissections were graded according to the modified classification of the Heart, Lung, and Blood Institute (9). Given the relatively low incidence of coronary dissections, the patient population was analyzed on the basis of the presence or absence of any dissection type. The sizing of the implanted coronary stent(s) was evaluated by visual estimate. It is important to note that the stent deployment was judged on the basis of angiographic appearance and not by quantitative coronary analysis or intravascular ultrasound (IVUS) analysis. Undersizing of the coronary stent(s) was considered significant as 1 of the following criteria was met: 1) the stent to the reference segment diameter ratio was <1; 2) inappropriate alignment of the coronary stent with the coronary vessel wall; and 3) mismatch in post-deployment stent dimensions in relation to the proximal and distal segments of the target vessel.
The presence of intermediate coronary artery disease (CAD), defined as a visually estimated percentage of coronary stenosis of 50% but  70%, proximal and distal to the stented segment(s) of the target vessel were also scored.
Statistical analysis.
Continuous variables were presented as mean ± SD and were compared with the Student t test or Mann-Whitney U test. The chi-square or Fisher exact test was used to analyze differences in categorical variables. Conditional logistic regression analysis was performed to determine independent predictors of ST. Selected variables were first entered into the univariate analysis. Variables with p < 0.05 by univariate analysis were then entered in the conditional logistic regression analysis for identification of predictors of ST.
To study the impact of the determinant "lack of clopidogrel therapy at different time points after the index PCI (<24 h, 1 to 30 days, >30 days to 6 months, and beyond)" a multivariable Cox proportional hazards model was created with "lack of clopidogrel therapy at the time of ST" as time varying covariates. For this analysis, it was assumed that the time-interval between index PCI and the "virtual ST" of the control patients was exactly the same as that for its matched case. All patients with ST and their matched control subjects were also further subdivided into 3 groups: 1) those who were taking clopidogrel at the ("virtual") time of ST; 2) those who had discontinued the clopidogrel within 14 days before the ST; and 3) those who had discontinued the clopidogrel longer than 14 days before the ST (it is important to note that we also made an attempt to perform a sensitivity analysis with varying time-intervals for the time between clopidogrel cessation and the ST; however, due to the relatively small patient groups with late and very late ST who discontinued the clopidogrel treatment, no reliable estimates could be provided when the time interval between clopidogrel cessation and the occurrence of ST exceeded 14 days; for the first 14 days, the hazard ratio [HR] remained relatively constant [data not shown]).
The independent "baseline" predictors of ST from conditional logistic regression analysis were also included in this model. All tests were 2-tailed and used a p value <0.05 to characterize statistical significance.
|
Results
|
|---|
During the study period, a total of 21,009 patients underwent stent implantation in the participating hospitals. A total of 31,065 stents were implanted (19,840 BMS and 11,225 DES). As expected, there were significant differences in age, prevalence of cardiovascular risk factors, lesion characteristics, and the prevalence of other clinical comorbidities between patients who received a BMS and patients who received a DES (Table 1). During a median follow-up of 30.9 months (25th to 75th percentiles: 23.6 to 41.9 months), 437 patients (2.1%) presented with an angiographic confirmed ST. According to the different categories of ST, 140 (32.0%) were acute ST, 180 (41.2%) were subacute ST, 58 (13.3%) were late ST (36 within 6 months), and 59 were very late (13.5%). Two-hundred seventy STs were related to a BMS (cumulative incidence: 2.2%), 152 stent thromboses were related to a DES (cumulative incidence: 2.0%), and 15 were related to both a BMS and a DES stent (mixed use, cumulative incidence: 1.8%). The cumulative incidence of ST was not significantly different between the 2 different types of coronary stents: p = 0.38).
We were able to match 866 control subjects to the case subjects (99.0%). Detailed clinical, procedural, and angiographic features of the patients with ST and the matched control subjects are described in Table 2.
Comprehensive risk-factor identification: all cases versus all matched control subjects.
Independent clinical, procedural, and angiographic predictors of ST when comparing all cases with all matched control subjects in multivariate analysis are depicted in Figure 1. Cessation of clopidogrel at various time points, undersizing, present malignant disease, the presence of intermediate CAD proximal to the culprit lesion, suboptimal procedural result (Thrombolysis In Myocardial Infarction [TIMI] flow grade <3 after PCI), uncovered dissection, bifurcation stenting, left ventricular ejection fraction (LVEF) <30%, peripheral artery disease, the presence of intermediate CAD distal to the culprit lesion, no aspirin therapy, diabetes mellitus, use of any DES, and younger age were associated with the occurrence of ST.
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Independent Risk Factors for ST
A comparison of the total group of patients with stent thrombosis (ST) with all matched-control subjects. Represented by hazard ratio (HR) and 95% confidence interval (CI). ASA = acetyl salicylic acid; CAD = coronary artery disease; DES = drug-eluting stent(s); DM = diabetes mellitus; LVEF = left ventricular ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction.
|
|
Influence of the indication for the index PCI on ST rate and determinants of ST.
With regard to the different indications for stent implantation, the cumulative incidence of ST in patients who underwent an elective PCI for the indication stable angina pectoris was low (113 of 11.207 patients, cumulative incidence: 1.00%). However, the cumulative incidence of ST was higher when the indication for index stent implantation was unstable angina/NSTEMI (72 of 3,960 patients, cumulative incidence: 1.8%) and STEMI (252 of 5,842, cumulative incidence: 4.3%). The timing of ST was also significantly different throughout the different indications for stent implantation (p = 0.0003). The STEMI patients experienced an early ST significantly more often (79% of all STs in STEMI patients were early vs. 65% of all STs in stable angina and NSTEMI patients), whereas the proportion of late and very late ST was higher in the stable angina and NSTEMI group.
Determinants of ST for the different indications of index stent implantation are depicted in Figure 2. Independent factors that predispose to the development of ST in patients undergoing elective PCI with stent implantation for the indication stable angina were undersizing, the presence of intermediate CAD proximal to the culprit lesion, malignant disease, suboptimal procedural result (TIMI flow grade <3 after PCI), LVEF <30%, uncovered dissection, multivessel disease, left descending coronary artery stenting, and long total stent length. Predictors of ST in the setting of ACS (including STEMI) as the indication for index PCI were undersizing, suboptimal procedural result (TIMI flow grade <3 after PCI), uncovered dissection, the presence of intermediate CAD proximal to the culprit lesion, bifurcation lesion, any DES, no aspirin therapy, LVEF <30%, the presence of intermediate CAD distal to the culprit lesion, and multivessel disease. Of note, periprocedural use of glycoprotein IIb/IIIa therapy for the indication ACS (including STEMI) was associated with a reduction of ST. It is important to note that the time-varying covariable "cessation of clopidogrel" was not included in these multivariate models.
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Independent Risk Factors for ST for the Different Indications of Index Stent Implantation
(A) Cases and matched controls with stable angina as indications for index PCI. (B) Cases and matched controls with acute coronary syndrome as indication for index PCI. Represented by odds ratio (OR) and 95% CI. GP = glycoprotein; LAD = left anterior descending; other abbreviations as in Figure 1.
|
|
Risk factors for early ST and late ST.
Almost 75% of the STs occurred within 30 days after stent implantation. Figure 3
displays the independent predictors of early ST (30 days after the index PCI) with associated odds ratios and 95% confidence interval (CI) and the independent predictors of late ST (>30 days after the index PCI). Early predictors of ST included undersizing, uncovered dissection, suboptimal procedural result (TIMI flow grade <3 after PCI), the presence of intermediate CAD proximal to the culprit lesion, present malignant disease, no aspirin, LVEF <30%, bifurcation lesion, the presence of intermediate CAD distal to the culprit lesion, any DES, and total number of stents. Glycoprotein IIb/IIIa was protective for the occurrence of early ST.
The following determinants were independently associated with the occurrence of late ST: undersizing, present malignant disease, the presence of intermediate CAD proximal to the culprit lesion, peripheral artery disease, diabetes mellitus, bifurcation lesions, long total stent length, and younger age.
Again, it is important to note that the time-varying covariable "cessation of clopidogrel" was not included in these multivariate models.
The influence of antiplatelet therapy on the occurrence of ST.
The proportion of cases and matched control subjects that were receiving clopidogrel therapy for the time-frames of the different categories of ST is presented in Figure 4. In detail, a total of 134 (30.7%) cases were not taking clopidogrel therapy at the time of the ST. Of these, in 9 of 140 (6.4%) patients presenting with an acute ST, the clopidogrel was erroneously not initiated; 30 of 179 (16.7%) patients with a subacute ST had discontinued the clopidogrel for a median of 5 days (interquartile range: 3 to 7 days); 39 of 58 (67.2%) patients with a late ST had discontinued the clopidogrel for a median of 13 days (interquartile range: 7 to 61 days); and 56 of 59 (94.9%) patients with a very late ST had discontinued the clopidogrel for a median of 200 days (interquartile range: 23 to 981 days).
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Adherence to Clopidogrel Therapy
Proportion of cases and their matched control subjects taking clopidogrel therapy according to the elapsed time between stent implantation and the occurrence of stent thrombosis (ST).
|
|
After applying the exact elapsed time-frame between the index PCI and ST for every case to their matched control subjects, we show that a significant higher proportion of control subjects were taking clopidogrel therapy at the "virtual time" of occurrence of ST (Fig. 4). The lack of clopidogrel therapy at the time of ST in the first 30 days after the index PCI was strongly associated with ST (HR: 36.5, 95% CI: 8.0 to 167.8). Likewise, the lack of clopidogrel therapy at the time of ST between 30 days and 6 months after the index PCI was also linked to the occurrence of ST (HR: 4.6, 95% CI: 1.4 to 15.3). Multivariate Cox proportional hazard analysis also found that discontinuation of clopidogrel therapy after 6 months from the index stent implantation was a predictor of ST (HR: 5.9, 95% CI: 1.7 to 19.8).
Alternatively, given the fact that clopidogrel irreversibly inhibits the human platelet throughout its entire lifespan (10 to 12 days), we hypothesized that cessation of clopidogrel <14 days before the ST would reveal the temporal relationship between the discontinuation of clopidogrel and ST. After introducing this time-varying covariate in the multivariate Cox proportional hazard model, "cessation of clopidogrel within 14 days before ST" in the first 30 days after the index PCI emerged as a highly significant predictor of ST (HR: 36.9, 95% CI: 7.9 to 173.3). Similarly, "cessation of clopidogrel within 14 days before ST" between 30 days and 6 months after the index PCI was also independently associated with the occurrence of ST (HR: 21, 95% CI: 2.2 to 198.3). The number of events beyond the 6-month time-frame after stent implantation was too small to reliably estimate the impact of "cessation of clopidogrel and the subsequent occurrence of ST within 14 days" on the occurrence of ST in this subcategory of patients.
Another important finding relates to the magnitude of impact of "cessation of clopidogrel and the subsequent occurrence of ST within 14 days" between DES and BMS. The risk for ST associated with "cessation of clopidogrel and the subsequent occurrence of ST within 14 days" was significantly higher in patients who had received a DES as compared with those who had received a BMS (odds ratio for DES: 1.88, 95% CI: 1.21 to 2.94, p = 0.0052).
A significantly higher percentage of the patients with ST did not use aspirin therapy at the time of the index as compared with their matched control (13.1% vs. 4.5%, p < 0.0001). The predominant reasons for no aspirin treatment were Coumadin use in 85 of 96 (84.4%) patients and allergy to aspirin in 7 of 96 (7.3%) patients. Multivariate logistic regression analysis identified that the absence of aspirin therapy was also a strong independent predictor of ST (HR: 1.91 95% CI: 1.01 to 3.88, p = 0.0487).
|
Discussion
|
|---|
Given the devastating consequences of ST, great efforts should be directed to identify those patients at highest risk, who would probably benefit most from an alternative strategy. The findings of the present study add considerably to the understanding of the profiles of patients at high risk for ST.
Although previous studies have already recognized multiple risk factors that confer a significant risk of ST (1–3,5,7,10), many of these studies have limitations, mostly related to an overall small sample size with a limited number of cases. Also, the identified determinants of ST represent those that have been looked for, and many theoretical likely factors (such as present malignancy, severity of atherosclerotic disease, aspirin use) are not investigated in most published studies.
The case-control design of our study as well as the acquisition of very detailed data on medical history, medication use, and angiographic characteristics enabled us to comprehensively examine the most important risk factors that are associated with ST. Moreover, the large sample size allowed identification of relatively infrequent determinants.
The highly variable duration of clopidogrel use throughout the years of patient recruitment (2004 to 2007) allowed us to comprehensively study the impact of early clopidogrel cessation after stent implantation. As expected, lack of clopidogrel therapy at the time of the ST in the first 6 months after the index PCI was identified as the strongest independent predictor of ST, and this observation is in line with some (1,2,11) but not all (3,7) previous reports. Also, we predefined a likely "vulnerable time-frame" between cessation of clopidogrel and the occurrence of ST (<14 days) and demonstrated that this is the period that patients are at the highest risk for ST, especially when the discontinuation of clopidogrel was within the first 6 months after stent implantation.
A novel and very important finding of the present study, contrary to a recently published study (7), is that the lack of clopidogrel therapy (but not necessarily cessation of clopidogrel within the 14 days preceding the ST) beyond 6 months after index PCI was a predictor of ST. A likely explanation for this difference might be that previous studies were hampered by a very low number of events (16 patients, of whom 7 did not use clopidogrel at time of ST) >6 months after coronary stent implantation (7). Nonetheless, our results should also be interpreted with caution, because only a small portion of patients with ST beyond 6 months had discontinued the clopidogrel in the 14 days preceding the ST.
It remains pure speculative as to why "lack of clopidogrel therapy after 6 months from the index stent implantation" but not "cessation of clopidogrel and the occurrence of ST (<14 days)" beyond 6 months was a predictor of late and very late ST. Perhaps the loss of protection by clopidogrel therapy rather than a "rebound in platelet reactivity" might explain these findings.
Undersizing of the coronary stent was the second strongest predictor of ST in our study. Indeed, previous studies have elucidated the importance of correct sizing of coronary stents, in particular in patients with a high thrombotic burden with subsequent vasoconstriction or severe and diffuse target vessel disease (12–16). Previous reports have suggested that, despite improvements in techniques and materials in the last decade, the incidence of incomplete stent deployment and undersizing ranges from 20% to 30%, and this percentage is even higher when assessed by IVUS (15,17). Notwithstanding the results of previous studies suggesting that the judgment of the correct sizing and/or deployment of coronary stents is superior with the use of IVUS (18), we demonstrated that the identification of undersizing of a coronary stent by the simple means of eyeballing is a strong predictor of ST. In most of the cases, undersizing was probably due to severe calcification or related to a high thrombotic burden with subsequent vasoconstriction. However, incorrect judgment of the true coronary vessel size by the performing operator is also a likely explanation for undersizing in a considerable number of cases.
The long-term safety of DES has been a main topic of debate at recent international cardiology meetings. In our study, patients who received a DES had higher baseline risk-profiles and more complex lesion characteristics. Nonetheless, the use of a DES was not independently associated with late or very late ST. In contrast, any DES use was independently associated with ST in both the all-cases versus all-control subjects analysis as well as in the sub analysis on risk factors for early ST.
Several previous studies have elucidated the importance of mechanical (both angiographic and procedural factors) etiologies underlying early ST (12,15,17). Given the more complex lesion characteristics (an off-label DES indication) and limited flexibility of the first generation of DES, uncovered endothelial damage during DES implantation might explain this association between early ST and DES use.
Study limitations.
Several limitations of the present study need to be acknowledged. First, notwithstanding that a case-control design enables the evaluation of rare events such as ST, a case-control design is at the same time vulnerable to several sorts of bias. Indeed, 3 control patients were excluded from analysis because they were admitted for ST in another nonparticipating hospital during follow-up. However, given the size of the control group (2:1 ratio), the random selection of control subjects and the extent of differences in clinical procedural and angiographic findings between cases and control subjects, it is unlikely that the results would have changed considerably by increasing the number of control subjects. Second, only angiographically documented cases with ST ("definite") were reported. This might have led to an underestimation of the actual incidence of ST, because patients who had suffered from a sudden cardiac death or from a silent stent occlusion were not included in our analysis. Third, one might question our evaluation of the sizing of coronary stents by simple means of eyeballing instead of using sophisticated techniques such as IVUS or quantitative coronary analysis. Nonetheless, visual estimation was able to detect undersizing in 18.1% of the cases and in only 2.3% of the control subjects, which makes it a valuable tool.
|
Conclusions
|
|---|
We identified several important predictors of ST in the contemporary era of mixed DES and BMS use. Discontinuation of clopidogrel, undersizing of the coronary stent, presence of intermediate CAD proximal to the culprit lesion, and concomitant malignant disease were the strongest predictors of ST. Risk factors for ST also vary throughout the different indications for PCI (stable angina vs. ACS) and differ for the different categories of ST (early vs. late ST).
|
Footnotes
|
|---|
The Dutch Stent Thrombosis Registry was supported by an unrestricted research grant from Sanofi-Aventis and Bristol-Myers Squibb. The sponsor had no role in the design and conduct of the study in the collection, management, analysis, and interpretation of the data or in the preparation, review, or approval of the manuscript. Drs. van Werkum and ten Berg served on scientific advisory boards for The Medicines Company. Dr. Verheugt received speaker fees from Sanofi-Aventis and received funding for research from Bayer and Eli Lilly. The supporting pharmaceutical company Sanofi-Aventis had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Drs. van Werkum, Heestermans, and ten Berg had full access to all data and had final responsibility for the decision to submit for publication.
|
References
|
|---|
1. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 2005;293:2126-2130.[Abstract/Free Full Text]2. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents Circulation 2006;113:1108-1113.[Abstract/Free Full Text] 3. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 2007;369:667-678.[CrossRef][Medline] 4. Smit JJ, van't Hof AW, de Boer MJ, et al. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction Thromb Haemost 2006;96:190-195.[Web of Science][Medline] 5. Rinaldi MJ, Kirtane AJ, Piana RN, et al. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events Am Heart J 2008;155:654-660.[CrossRef][Web of Science][Medline] 6. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 2006;48:2584-2591.[Abstract/Free Full Text] 7. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 2007;116:745-754.[Abstract/Free Full Text] 8. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 2007;115:2344-2351.[Abstract/Free Full Text] 9. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty Am J Cardiol 1991;68:467-471.[CrossRef][Web of Science][Medline] 10. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up Am J Cardiol 2006;98:352-356.[CrossRef][Web of Science][Medline] 11. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials Circulation 2001;103:1967-1971.[Abstract/Free Full Text] 12. Moussa I, Di MC, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome J Am Coll Cardiol 1997;29:6-12.[Abstract] 13. Takano Y, Yeatman LA, Higgins JR, et al. Optimizing stent expansion with new stent delivery systems J Am Coll Cardiol 2001;38:1622-1627.[Abstract/Free Full Text] 14. Brodie BR, Cooper C, Jones M, Fitzgerald P, Cummins F. Is adjunctive balloon postdilatation necessary after coronary stent deployment?. Final results from the POSTIT trial. Catheter Cardiovasc Interv 2003;59:184-192.[CrossRef][Web of Science][Medline] 15. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study Circulation 2003;108:43-47.[Abstract/Free Full Text] 16. Cheneau E, Satler LF, Escolar E, et al. Underexpansion of sirolimus-eluting stents: incidence and relationship to delivery pressure Catheter Cardiovasc Interv 2005;65:222-226.[CrossRef][Web of Science][Medline] 17. Uren NG, Schwarzacher SP, Metz JA, et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry Eur Heart J 2002;23:124-132.[Abstract/Free Full Text] 18. Briguori C, Tobis J, Nishida T, et al. Discrepancy between angiography and intravascular ultrasound when analysing small coronary arteries Eur Heart J 2002;23:247-254.[Abstract/Free Full Text]
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A30.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. J. Armstrong, K. K. Yeo, U. Javed, E. Mahmud, M. Patel, K. A. Shunk, J. S. MacGregor, R. I. Low, and J. H. Rogers
Angiographic Stent Thrombosis at Coronary Bifurcations: Short- and Long-Term Prognosis
J. Am. Coll. Cardiol. Intv.,
January 1, 2012;
5(1):
57 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Roth, N. E. Morden, W. Zhou, D. J. Malenka, and J. Skinner
Clopidogrel Use and Early Outcomes Among Older Patients Receiving a Drug-Eluting Coronary Artery Stent
Circ Cardiovasc Qual Outcomes,
January 1, 2012;
5(1):
103 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, S. M. Hollenberg, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
J. Am. Coll. Cardiol.,
December 6, 2011;
58(24):
e44 - e122.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Circulation,
December 6, 2011;
124(23):
e574 - e651.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Granada, M. J. Price, P. A. French, S. R. Steinhubl, D. E. Cutlip, R. C. Becker, S. S. Smyth, and H. L. Dauerman
Platelet-Mediated Thrombosis and Drug-Eluting Stents
Circ Cardiovasc Interv,
December 1, 2011;
4(6):
629 - 637.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cayla, J.-S. Hulot, S. A. O'Connor, A. Pathak, S. A. Scott, Y. Gruel, J. Silvain, J.-B. Vignalou, Y. Huerre, A. de la Briolle, et al.
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis
JAMA,
October 26, 2011;
306(16):
1765 - 1774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. W. A. Verheugt
Triple Antithrombotic Therapy After Coronary Stenting: Why Expert Opinion Is Necessary
Circ Cardiovasc Interv,
October 1, 2011;
4(5):
410 - 412.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes Jr, D. L. Bhatt, D. J. Moliterno, R. C. Becker, and D. J. Angiolillo
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary
Circ Cardiovasc Interv,
October 1, 2011;
4(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gaglia Jr and R. Waksman
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes
Eur. Heart J.,
October 1, 2011;
32(19):
2358 - 2364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, C. S. Barker, M. B. Leon, L. Mauri, W. Wijns, J. Fajadet, and R. Mehran
Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1119 - 1128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane and G. W. Stone
How to Minimize Stent Thrombosis
Circulation,
September 13, 2011;
124(11):
1283 - 1287.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Brown and J. K. Bussell
Medication Adherence: WHO Cares?
Mayo Clin. Proc.,
April 1, 2011;
86(4):
304 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma and P. W. Serruys
Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?
Circulation,
February 22, 2011;
123(7):
779 - 797.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Mahmoud, R. J. Lennon, H. H. Ting, C. S. Rihal, and D. R. Holmes Jr
Circadian Variation in Coronary Stent Thrombosis
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
183 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Harmsze, J. W. van Werkum, J. M. ten Berg, B. Zwart, H. J. Bouman, N. J. Breet, A. W. J. van 't Hof, H. J. T. Ruven, C. M. Hackeng, O. H. Klungel, et al.
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
Eur. Heart J.,
December 2, 2010;
31(24):
3046 - 3053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, S. Garg, P. W. Serruys, G. J. Dehmer, S. G. Ellis, D. O. Williams, T. Kimura, and D. J. Moliterno
Stent Thrombosis
J. Am. Coll. Cardiol.,
October 19, 2010;
56(17):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kimura, T. Morimoto, K. Kozuma, Y. Honda, T. Kume, T. Aizawa, K. Mitsudo, S. Miyazaki, T. Yamaguchi, E. Hiyoshi, et al.
Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents: Observations From the Registry of Stent Thrombosis for Review and Reevaluation (RESTART)
Circulation,
July 6, 2010;
122(1):
52 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
May 18, 2010;
55(20):
2272 - 2286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. El-Menyar, H. Hussein, and J. Al Suwaidi
Coronary Stent Thrombosis in Patients With Chronic Renal Insufficiency
Angiology,
April 1, 2010;
61(3):
297 - 303.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Savonitto, M. D'Urbano, M. Caracciolo, F. Barlocco, G. Mariani, M. Nichelatti, S. Klugmann, and S. De Servi
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel
Br. J. Anaesth.,
March 1, 2010;
104(3):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Breet, J. W. van Werkum, H. J. Bouman, J. C. Kelder, H. J. T. Ruven, E. T. Bal, V. H. Deneer, A. M. Harmsze, J. A. S. van der Heyden, B. J. W. M. Rensing, et al.
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
JAMA,
February 24, 2010;
303(8):
754 - 762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vasa-Nicotera and T. Gershlick
Chapter 29 Stent thrombosis
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. E. Kandzari, D. J. Angiolillo, M. J. Price, and P. S. Teirstein
Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Montalescot, J.-S. Hulot, and J.-P. Collet
Stent thrombosis: who's guilty?
Eur. Heart J.,
November 2, 2009;
30(22):
2685 - 2688.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, A. Colombo, S.-J. Park, C. L. Tommaso, S. G. Ellis, L. A. Guzman, P. S. Teirstein, C. Tamburino, J. Ormiston, G. W. Stone, et al.
Revascularization for Unprotected Left Main Disease: Evolution of the Evidence Basis to Redefine Treatment Standards
J. Am. Coll. Cardiol.,
October 20, 2009;
54(17):
1576 - 1588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
October 13, 2009;
54(16):
1544 - 1555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. George and T. A. Bass
Health Care Reform Bill H. R. 3200--America's Affordable Health Choices Act: What Is Missing?
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
1028 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods